BrightGene's Oral GLP-1/GIP Dual Agonist BGM0504 Shows Promising Weight Loss Results in Phase 1 Trials
核心洞察
BrightGene reported positive Phase 1 results for BGM0504, an oral GLP-1 (搜索)/GIP (搜索) dual receptor agonist, demonstrating weight reductions of 1.0% to 5.6% in China and 2.7% to 8.2% in the U.S. after 4-8 weeks of treatment.
The investigational drug was generally well tolerated across both studies with no serious adverse events, and gastrointestinal side effects were predominantly mild to moderate and transient.
BGM0504 achieved steady-state exposure after 2-3 weeks with dose-proportional pharmacokinetics, supporting once-daily oral dosing for obesity treatment.
BrightGene Bio-Medical Technology Co., Ltd. announced positive topline results from Phase 1 clinical studies of BGM0504, an investigational oral GLP-1 (搜索)/GIP (搜索) dual receptor agonist, conducted in China and the United States. The studies evaluated the drug's safety, tolerability, and preliminary efficacy in healthy volunteers and individuals with overweight or obesity.
Safety and Tolerability Profile
Across both studies, BGM0504 demonstrated a favorable safety profile with no serious adverse events reported. The most commonly observed adverse events were gastrointestinal in nature, consistent with the known profile of this drug class. These events were predominantly mild to moderate in severity and transient in duration.
The China Phase 1 study enrolled 75 participants who completed the trial, while the U.S. study included 80 participants, with 64 receiving BGM0504 and 16 receiving placebo. All participants tolerated the treatment well across the tested dose ranges.
Efficacy Results Show Dose-Dependent Weight Loss
Preliminary efficacy analyses revealed meaningful reductions in body weight across both studies. In the China Phase 1 study, participants demonstrated mean body weight reductions ranging from 1.0% to 5.6% after four weeks of treatment. The U.S. study showed even more pronounced results, with mean body weight reductions ranging from 2.7% to 8.2% after five to eight weeks of treatment.
The U.S. study specifically demonstrated a dose response in weight reduction, suggesting the drug's efficacy increases with higher doses within the tested range.
Study Design and Pharmacokinetics
The China Phase 1 study (CTR20253763 / NCT07239973) was a randomized, double-blind, placebo-controlled trial. BGM0504 was administered once daily at doses ranging from 10 mg to 80 mg for four weeks. Pharmacokinetic analyses revealed that steady-state exposure was achieved after approximately two to three weeks of dosing, with exposure increasing in a generally dose-proportional manner.
The U.S. Phase 1 study (NCT07166081) employed a randomized, placebo-controlled, multiple ascending dose design. Participants received once-daily dosing across dose levels ranging from 20 mg to 80 mg, with treatment durations of five to eight weeks depending on the dose cohort, ensuring at least four weeks of dosing at the target dose.
Development Strategy and Future Plans
BGM0504 is being developed in both oral and subcutaneous formulations as part of BrightGene's broader strategy in obesity and related metabolic diseases. The subcutaneous formulation is at a more advanced stage of development, with China Phase 2 studies and a U.S. bridging study completed, and multiple Phase 3 studies currently ongoing.
Detailed results from these Phase 1 studies are expected to be presented at a scientific conference later this year. The company notes that the disclosed data are based on preliminary analyses of ongoing clinical studies, and results may be subject to change as additional data become available and further analyses are conducted.
BGM0504 remains an investigational drug and has not been approved for marketing in any country. The company emphasizes that drug development involves substantial risks and uncertainties, and clinical trial results may not be predictive of future outcomes.